Novocure (NASDAQ: NVCR) announced that its Optune Pax device has received CE Mark approval for the treatment of adult patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE